Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Journal:

Arthritis & Rheumatology

Published:

2026-02-11

DOI:

10.1002/art.70092

Affiliations:

10

Authors:

13

Go to article

Institutions	Authors	Share
Johnson & Johnson, United States of America (USA)	6.500000	0.50
The University of Texas Southwestern Medical Center (UT Southwestern Medical Center), United States of America (USA)	2.000000	0.15
University of Pennsylvania (Penn), United States of America (USA)	1.000000	0.08
University of Rochester Medical Center (URMC), UR, United States of America (USA)	1.000000	0.08
NYU Langone Health, United States of America (USA)	1.000000	0.08
Providence Swedish, United States of America (USA)	0.500000	0.04
UW Medicine, United States of America (USA)	0.500000	0.04
Drexel University, United States of America (USA)	0.500000	0.04

Interested in Clinical Sciences?